|
Name |
8-Propionyl-neosolaniol
|
Molecular Formula | C22H30O9 | |
IUPAC Name* |
[(2R,4S,10R,11S)-11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] propanoate
|
|
SMILES |
CCC(=O)O[C@H]1C[C@]2(C(C=C1C)OC3[C@@H]([C@H](C2(C34CO4)C)OC(=O)C)O)COC(=O)C
|
|
InChI |
InChI=1S/C22H30O9/c1-6-16(25)30-14-8-21(9-27-12(3)23)15(7-11(14)2)31-19-17(26)18(29-13(4)24)20(21,5)22(19)10-28-22/h7,14-15,17-19,26H,6,8-10H2,1-5H3/t14-,15?,17+,18+,19?,20?,21+,22?/m0/s1
|
|
InChIKey |
ZSGWJLBSFZRJAT-ZCJGQMPNSA-N
|
|
Synonyms |
8-propionylneosolaniol; 8-Propionyl-neosolaniol; P-NEO
|
|
CAS | NA | |
PubChem CID | 102515220 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 438.5 | ALogp: | 0.1 |
HBD: | 1 | HBA: | 9 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 121.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 31 | QED Weighted: | 0.294 |
Caco-2 Permeability: | -5.261 | MDCK Permeability: | 0.00007210 |
Pgp-inhibitor: | 0.961 | Pgp-substrate: | 0.993 |
Human Intestinal Absorption (HIA): | 0.357 | 20% Bioavailability (F20%): | 0.374 |
30% Bioavailability (F30%): | 0.957 |
Blood-Brain-Barrier Penetration (BBB): | 0.305 | Plasma Protein Binding (PPB): | 32.40% |
Volume Distribution (VD): | 1.044 | Fu: | 44.77% |
CYP1A2-inhibitor: | 0.016 | CYP1A2-substrate: | 0.086 |
CYP2C19-inhibitor: | 0.023 | CYP2C19-substrate: | 0.648 |
CYP2C9-inhibitor: | 0.012 | CYP2C9-substrate: | 0.044 |
CYP2D6-inhibitor: | 0.021 | CYP2D6-substrate: | 0.118 |
CYP3A4-inhibitor: | 0.345 | CYP3A4-substrate: | 0.401 |
Clearance (CL): | 3.347 | Half-life (T1/2): | 0.233 |
hERG Blockers: | 0.02 | Human Hepatotoxicity (H-HT): | 0.624 |
Drug-inuced Liver Injury (DILI): | 0.835 | AMES Toxicity: | 0.427 |
Rat Oral Acute Toxicity: | 0.937 | Maximum Recommended Daily Dose: | 0.175 |
Skin Sensitization: | 0.066 | Carcinogencity: | 0.125 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.013 |
Respiratory Toxicity: | 0.102 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002259 | 0.874 | D0G7KJ | 0.285 | ||||
ENC003580 | 0.870 | D0L2UN | 0.279 | ||||
ENC001179 | 0.859 | D0OL7F | 0.275 | ||||
ENC003104 | 0.826 | D09SIK | 0.275 | ||||
ENC003086 | 0.742 | D0H2MO | 0.271 | ||||
ENC005517 | 0.729 | D09IEE | 0.270 | ||||
ENC005516 | 0.707 | D01ZOG | 0.268 | ||||
ENC005586 | 0.598 | D08BDT | 0.266 | ||||
ENC005587 | 0.425 | D0X2LV | 0.262 | ||||
ENC005782 | 0.336 | D09WYX | 0.257 |